In NOD/SCID mice, CXCR4 inhibitor AMD3465 mobilized human FLT3-ITD AML LSC, defined immunophenotypically as CD34+ CD123+, up to 7.5-fold (Zeng et al., 2009). This evidence concerns the gene CD34 and acute myeloid leukemia.